Authors' Response

Affiliations

¹ Division of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
³ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address: mark_awad@dfci.havard.edu.

Free article

Comment

Matthew P Cheng et al. J Thorac Oncol. 2018 Nov.

Free article

. 2018 Nov;13(11):e237.

doi: 10.1016/j.jtho.2018.09.015.

¹ Division of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
³ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address: mark_awad@dfci.havard.edu.

No abstract available

Comment on

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM. Ostios-Garcia L, et al. J Thorac Oncol. 2018 Jul;13(7):1037-1042. doi: 10.1016/j.jtho.2018.03.031. Epub 2018 Apr 6. J Thorac Oncol. 2018. PMID: 29631035
Immune Checkpoint Inhibitors in HIV-Positive Patients With NSCLC: Is it Time for Outlining a Protocol?
Mormile R. Mormile R. J Thorac Oncol. 2018 Nov;13(11):e236-e237. doi: 10.1016/j.jtho.2018.08.2018. J Thorac Oncol. 2018. PMID: 30368419 No abstract available.